Stock analysts at StockNews.com began coverage on shares of Johnson & Johnson (NYSE:JNJ – Get Rating) in a note issued to investors on Thursday. The brokerage set a “strong-buy” rating on the stock.
Several other brokerages have also commented on JNJ. Guggenheim started coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective on the stock. Atlantic Securities upped their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a report on Wednesday, January 25th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 25th. Piper Sandler cut their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $174.73.
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $154.35 on Thursday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The firm has a market capitalization of $401.97 billion, a price-to-earnings ratio of 22.90, a PEG ratio of 2.61 and a beta of 0.54. The company’s 50-day moving average is $163.02 and its two-hundred day moving average is $168.05. Johnson & Johnson has a 1-year low of $150.71 and a 1-year high of $186.69.
Insider Activity at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.35% of the company’s stock.
Institutional Trading of Johnson & Johnson
A number of large investors have recently bought and sold shares of JNJ. DORCHESTER WEALTH MANAGEMENT Co boosted its stake in Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after purchasing an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P boosted its stake in Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after purchasing an additional 82,429 shares during the period. AMI Investment Management Inc. boosted its stake in Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after purchasing an additional 1,475 shares during the period. Equitable Holdings Inc. boosted its stake in Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after purchasing an additional 2,119 shares during the period. Finally, USS Investment Management Ltd lifted its stake in shares of Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after acquiring an additional 20,528 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.